|
|
|
Insider
Information: |
Enright Patrick G |
Relationship: |
10% Owner |
City: |
Burlingame |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
16 |
|
Direct
Shares |
3,308,185 |
|
Indirect Shares
|
27,432,603 |
|
|
Direct
Value |
$8,963,626 |
|
|
Indirect Value
|
$114,702,131 |
|
|
Total
Shares |
30,740,788 |
|
|
Total
Value |
$123,665,757 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
6
|
1
|
Stock
price went up :
|
5
|
1
|
Stock
price went down : |
1
|
0
|
|
|
|
Gain/Loss Ratio : |
5.0
|
1.0
|
Percentage
Gain/Loss : |
95.0%
|
101.2%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Molecular Templates, Inc. |
MTEM |
Director |
2006-04-20 |
496 |
2007-03-01 |
0 |
Premium* |
|
Sequenom Inc |
SQNM |
Director |
2006-12-07 |
771 |
2006-12-07 |
3,333,333 |
Premium* |
|
Corcept Therapeutics Inc |
CORT |
Director |
2017-03-16 |
272,281 |
2017-03-16 |
114,675 |
Premium* |
|
Jazz Pharmaceuticals Inc |
JAZZ |
Director |
2023-08-14 |
20,946 |
2022-08-08 |
2,000 |
Premium* |
|
Esperion Therapeutics, Inc. |
ESPR |
Director |
2013-07-01 |
0 |
2015-03-19 |
18,361 |
Premium* |
|
Collegium Pharmaceutical, Inc |
COLL |
10% Owner |
2015-05-12 |
0 |
2015-05-12 |
65,270 |
Premium* |
|
Aimmune Therapeutics, Inc. |
AIMT |
Director |
2020-10-13 |
0 |
2020-10-10 |
0 |
Premium* |
|
Aptinyx Inc. |
APTX |
Director |
2020-01-10 |
95,000 |
2020-01-10 |
3,356,746 |
Premium* |
|
Tricida, Inc. |
TCDA |
|
2018-07-02 |
0 |
2018-07-02 |
3,019,734 |
Premium* |
|
Venus Concept Inc |
VERO |
10% Owner |
|
0 |
2019-11-07 |
3,666,119 |
Premium* |
|
89bio, Inc. |
ETNB |
10% Owner |
2019-11-11 |
0 |
2020-11-16 |
891 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
10% Owner |
2020-01-29 |
0 |
2022-01-25 |
1,964,771 |
Premium* |
|
Inozyme Pharma, Inc. |
INZY |
10% Owner |
2020-07-28 |
0 |
2022-04-19 |
4,174,379 |
Premium* |
|
Eargo, Inc. |
EAR |
10% Owner |
2021-04-14 |
2,918,691 |
2021-04-14 |
5,012 |
Premium* |
|
Vera Therapeutics, Inc. |
VERA |
Director, 10% Owner |
2021-05-18 |
0 |
2023-02-06 |
5,144,212 |
Premium* |
|
Lexeo Therapeutics, Inc. |
LXEO |
10% Owner |
2023-11-07 |
0 |
2023-11-07 |
2,567,100 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
169 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 7
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2015-08-11 |
4 |
B |
$16.00 |
$5,000,000 |
I/I |
312,500 |
7,434,630 |
2.25 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2015-08-11 |
4 |
A |
$0.00 |
$0 |
I/I |
7,122,130 |
7,122,130 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2016-03-29 |
4 |
B |
$13.50 |
$1,089,135 |
I/I |
78,504 |
7,513,134 |
2.25 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2016-11-29 |
4 |
A |
$0.00 |
$0 |
D/D |
7,276 |
7,276 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2016-11-29 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,500,000) |
6,013,134 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2018-02-22 |
4 |
B |
$32.00 |
$498,976 |
D/D |
15,593 |
22,869 |
3.92 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2018-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
3,750 |
26,619 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2019-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,442 |
33,061 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2019-09-17 |
4 |
A |
$22.34 |
$279,216 |
D/D |
12,500 |
45,561 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2020-03-17 |
4 |
B |
$11.50 |
$101,051 |
D/D |
8,787 |
54,348 |
2.39 |
% |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2020-03-17 |
4 |
B |
$11.40 |
$1,139,650 |
I/I |
100,000 |
6,113,134 |
2.1 |
% |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2020-03-18 |
4 |
B |
$11.06 |
$179,345 |
D/D |
16,213 |
70,561 |
2.39 |
% |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2020-05-27 |
4 |
S |
$0.00 |
$0 |
D/D |
(7,840) |
78,401 |
0 |
% |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2020-09-21 |
4 |
A |
$0.00 |
$0 |
I/I |
91,697 |
91,697 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2020-09-21 |
4 |
D |
$0.00 |
$0 |
I/I |
(6,113,134) |
0 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2020-10-10 |
4 |
D |
$34.50 |
$3,163,547 |
I/I |
(91,697) |
0 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2020-10-10 |
4 |
D |
$34.50 |
$2,434,355 |
D/D |
(70,561) |
0 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2020-10-13 |
4 |
D |
$34.50 |
$270,480 |
D/D |
(7,840) |
0 |
0 |
- |
|
APTX |
Aptinyx Inc. |
Director |
|
2018-06-25 |
4 |
B |
$16.00 |
$2,400,000 |
I/I |
150,000 |
3,190,079 |
2.1 |
- |
|
APTX |
Aptinyx Inc. |
Director |
|
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,040,079 |
3,040,079 |
0 |
- |
|
APTX |
Aptinyx Inc. |
Director |
|
2020-01-10 |
4 |
B |
$3.00 |
$285,000 |
D/D |
95,000 |
95,000 |
2.39 |
% |
|
APTX |
Aptinyx Inc. |
Director |
|
2020-01-10 |
4 |
B |
$3.00 |
$500,001 |
I/I |
166,667 |
3,356,746 |
2.1 |
% |
|
COLL |
Collegium Pharmaceutical,... |
10% Owner |
|
2015-05-12 |
4 |
B |
$12.00 |
$2,400,000 |
I/I |
200,000 |
65,270 |
1.5 |
- |
|
COLL |
Collegium Pharmaceutical,... |
10% Owner |
|
2015-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
3,121,842 |
61,340 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2008-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,530,450 |
|
- |
|
169 Records found
|
|
Page 1 of 7 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|